Anzeige
Mehr »
Freitag, 25.07.2025 - Börsentäglich über 12.000 News
Richtig investiert verwandelt der Goldpreis jeden Euro in glänzendes Vermögen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHG6 | ISIN: CA59935V1076 | Ticker-Symbol:
NASDAQ
24.07.25 | 22:00
1,570 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MILESTONE PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MILESTONE PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur MILESTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.07.Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development4
11.07.Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge3
11.07.Why Is Milestone Pharmaceuticals Stock Plunging On Friday?1
MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
11.07.Milestone Pharmaceuticals plunges after pricing $52.5M offering3
11.07.Milestone Pharmaceuticals prices $52.5 million public offering2
11.07.Milestone Pharmaceuticals stock plunges on public offering announcement4
11.07.Kapitalerhöhung angekündigt: Aktie von Milestone Pharmaceuticals bricht ein3
11.07.Milestone Pharmaceuticals proposes capital raise via securities offering1
11.07.Milestone Pharmaceuticals announces public offering of shares and warrants3
11.07.Milestone Pharmaceuticals Inc. - 8-K, Current Report1
11.07.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray236New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone®...
► Artikel lesen
17.06.Milestone Pharmaceuticals resubmits Cardamyst filing after FDA response4
16.06.Milestone Pharma Announces Submission Of Its Response To CRL Regarding NDA For CARDAMYST1
16.06.Milestone Pharmaceuticals submits response to FDA for PSVT drug3
12.06.Milestone Pharmaceuticals Inc. - 8-K, Current Report2
14.05.Milestone Pharmaceuticals GAAP EPS of -$0.31 misses by $0.1310
14.05.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update485Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) --...
► Artikel lesen
14.05.Milestone Pharmaceuticals Inc. - 8-K, Current Report1
14.05.Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report1
01.04.TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty4
Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1